<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-145334" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nuclear Medicine Applications in Prostate Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vyas</surname>
            <given-names>Madhusudan</given-names>
          </name>
          <aff>Te Pukenga, Auckland</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Henderson</surname>
            <given-names>Andrew M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Madhusudan Vyas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Henderson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-145334.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Prostate cancer is the 2nd most common cancer in men and the 4th overall. In 2020 , more than 1.4 million new prostate cancer cases were reported. In recent years, the incidence of prostate cancer has reached its highest levels due to more precise and timely diagnoses and an increase in average lifespan. Therefore, prostate cancer must be promptly diagnosed and treated to avoid high morbidity and mortality. This activity reviews the role of nuclear medicine in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications of nuclear medicine applications in prostate cancer.</p></list-item><list-item><p>Implement guideline-based PET-CT and SPECT-CT fusion imaging for prostate cancer diagnosis.</p></list-item><list-item><p>Apply best practices when dosing and administering radiopharmaceutical agents.</p></list-item><list-item><p>Select nuclear medicine imaging modalities to allow improved prostate cancer staging and restaging accuracy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145334&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145334">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-145334.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>In recent years, the incidence of prostate cancer has been the highest ever recorded due to earlier and more accurate detection and an increase in the average lifetime. Prostate cancer is now the second most common malignancy amongst all cancers in men and the fourth most common overall.</p>
        <p>The American Cancer Society has identified prostate cancer as the second leading cause of mortality from oncological causes in the United States, accounting for an estimated 268,490 newly diagnosed cases and 34,500 deaths in 2022. The National Cancer Institute predicts that the average American man has an 11% risk of being diagnosed with prostate cancer at some point in life and a 2.5% overall risk of dying from the disease.</p>
        <p>Globally, there were more than 1.4 million new cases of prostate cancer diagnosed worldwide in 2020, accounting for 375,304 deaths.<xref ref-type="bibr" rid="article-145334.r1">[1]</xref><xref ref-type="bibr" rid="article-145334.r2">[2]</xref><xref ref-type="bibr" rid="article-145334.r3">[3]</xref>&#x000a0;Prostate cancer&#x000a0;has been identified as the most commonly diagnosed malignancy in 112 countries worldwide and the leading cause of cancer mortality in 48.<xref ref-type="bibr" rid="article-145334.r2">[2]</xref><xref ref-type="bibr" rid="article-145334.r4">[4]</xref></p>
        <p>Timely diagnosis leading to earlier and more effective treatment is required to reduce the significant morbidity and mortality rates. Nuclear medicine has several new and revolutionary prostate cancer detection, localization, staging, and treatment tools&#x000a0;utilizing targeted therapy.<xref ref-type="bibr" rid="article-145334.r5">[5]</xref><xref ref-type="bibr" rid="article-145334.r6">[6]</xref>&#x000a0;The expanding role nuclear medicine plays in managing prostate cancer will be discussed in detail in the following review.</p>
      </sec>
      <sec id="article-145334.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>The prostate is a glandular and muscular organ located just below the neck of the bladder and at the base of the urethra.&#x000a0;The prostate's muscular function helps regulate urinary flow and prevents retrograde ejaculation, but its primary function is to produce a prostatic secretion that is added to the semen. Prostatic secretions include acid phosphatase, a prostatic growth regulator&#x000a0;that&#x000a0;helps release chemical energy from compounds in the semen; prostate-specific antigen, a protease that acts to liquefy the semen after ejaculation; transglutaminase, an enzyme that promotes liquefaction of semen; citric acid; zinc; and calcitonin, which improves sperm motility.<xref ref-type="bibr" rid="article-145334.r7">[7]</xref></p>
        <p>The prostate gland is situated within the pelvic cavity, immediately anterior to the rectum, below the inferior edge of the symphysis pubis, above the triangular ligament but below the inferior margin of the symphysis pubis.&#x000a0;The prostate's peak contacts the triangular ligament and is oriented downwards, while its base is below the bladder's neck.<xref ref-type="bibr" rid="article-145334.r8">[8]</xref> The base of the structure is oriented superiorly.&#x000a0;The&#x000a0;gland's anterior surface is attached to the pubis by the puboprostatic ligaments, while its posterior surface is in contact with the rectum's second section. The levator ani muscles contact the lateral surfaces of the gland.<xref ref-type="bibr" rid="article-145334.r8">[8]</xref><xref ref-type="bibr" rid="article-145334.r9">[9]</xref><xref ref-type="bibr" rid="article-145334.r10">[10]</xref></p>
        <p>The prostate comprises 5&#x000a0;lobes:&#x000a0;2&#x000a0;equally sized lateral lobes and the anterior, posterior, and median lobes.&#x000a0;The prostate is separated from the rectovesical fascia by a plexus of veins and is encased in a thin capsule composed of fibrous tissue. Muscular tissue can be found immediately below the capsule and surrounding the urethra.</p>
        <p>The arterial supply to the prostate is principally from the internal iliac circulation, specifically, the internal pudendal, inferior vesical, and hemorrhoidal or middle rectal arteries. The prostatic artery is the terminal branch of the inferior vesical artery.&#x000a0;The prostatic artery&#x000a0;is typically only 1&#x000a0;to 2 cm long before dividing into capsular and urethral branches. The venous drainage of the prostate is from the prostatic venous plexus and the dorsal vein of the penis into the internal iliac veins. The prostatic nerve supply is via the pelvic plexus and inferior hypogastric plexus.<xref ref-type="bibr" rid="article-145334.r8">[8]</xref><xref ref-type="bibr" rid="article-145334.r9">[9]</xref><xref ref-type="bibr" rid="article-145334.r10">[10]</xref><xref ref-type="bibr" rid="article-145334.r11">[11]</xref></p>
      </sec>
      <sec id="article-145334.s4" sec-type="Indications">
        <title>Indications</title>
        <p>After the early discovery of high-risk cancer (&#x0003e;Gleason 7, T3a or higher, PSA=20 or higher, ISUP=4 or higher), the most effective, definitive therapy for localized prostatic malignancies is radical prostatectomy and/or definitive radiation therapy. Approximately&#x000a0;80% of patients are cancer-free for 7&#x000a0;years, but&#x000a0;27% to 53% will eventually develop a recurrence.<xref ref-type="bibr" rid="article-145334.r12">[12]</xref>&#x000a0;The 5-year survival rate for patients with locally advanced prostate cancer is close to 100%; this drops to 31% for those with metastatic disease. Unfortunately, 12% of patients already have metastases to lymph nodes or other organs at diagnosis.<xref ref-type="bibr" rid="article-145334.r1">[1]</xref>&#x000a0;Those with metastases&#x000a0;have a significantly shorter survival time and are not likely to benefit from definitive, curative therapy.<xref ref-type="bibr" rid="article-145334.r13">[13]</xref><xref ref-type="bibr" rid="article-145334.r14">[14]</xref>&#x000a0;</p>
        <p>CT and&#x000a0;MRI are generally poor in detecting small lymph node metastases as they rely primarily on anatomical findings and nodal size characteristics.<xref ref-type="bibr" rid="article-145334.r15">[15]</xref>&#x000a0;Nuclear medicine bone scans typically require PSA levels of 20 ng/mL or more before reliably detecting metastatic bone lesions.<xref ref-type="bibr" rid="article-145334.r16">[16]</xref>&#x000a0;New nuclear medicine imaging modalities offer much more sensitive and specific detection of metastatic disease, allowing improved prostate cancer staging and restaging accuracy. This facilitates more appropriate and effective therapeutic choices while avoiding unnecessary morbidity from overtreatment, such as eliminating the need for definitive local therapy if there is already evidence of metastatic spread.</p>
        <p>Therapeutic radioligands designed for prostate cancer are also part of managing metastatic disease.&#x000a0;</p>
        <p>Historically, radiotherapeutic isotopes have played a significant role in the palliative treatment of painful bone metastases. However, in recent years, therapeutic radioligands targeting prostate-specific membrane antigen (PSMA), which is overexpressed on the cell surface membrane of most prostate cancers, have also been utilized successfully in several clinical trials.<xref ref-type="bibr" rid="article-145334.r1">[1]</xref><xref ref-type="bibr" rid="article-145334.r12">[12]</xref></p>
        <p>PSMA is a transmembrane cell surface glycoprotein highly expressed in up to 95% of prostate cancer cells, including castrate-resistant, aggressive, metastatic disease.<xref ref-type="bibr" rid="article-145334.r12">[12]</xref>&#x000a0;Emerging androgen resistance enhances PSMA overexpression (up to 1,000 times the normal level).<xref ref-type="bibr" rid="article-145334.r17">[17]</xref>&#x000a0;These characteristics make PSMA an excellent target for antibody-based tracers and small-molecule radiopharmaceuticals, including hormone-refractory disease progression, recurrence, or suspected metastases.</p>
        <p>The first available PSMA-based PET imaging radioligand was capromab pendetide radiolabeled with indium-111, known commercially as Prostascint&#x000a0;which was FDA-approved in 1996. Although a breakthrough, it could only bind to intracellular PSMA and had poor tissue penetration. This meant it could only effectively image nonviable cells with membrane damage exposing their intracellular contents. Imaging was also degraded by high background activity. These factors significantly limited its clinical utility and gave PSMA an initial bad reputation for prostate cancer imaging.<xref ref-type="bibr" rid="article-145334.r18">[18]</xref>&#x000a0;</p>
        <p>This changed radically on December 1, 2020, when the FDA approved the first successful small-molecule PSMA-based radioligand&#x000a0;that could highlight surface PSMA targets on living cancer cells. The development of small ligands which could reliably target active cell surface membrane PSMA sites has allowed widespread availability of prostate cancer radioligand-based imaging for staging and restaging, including castration-resistant tumors, even with very small tumor volumes and low PSA levels.</p>
        <p>PSMA-binding radionuclides are now widely used and recommended for primary staging, restaging, and early cancer detection. Therapeutic radioligands can be used in selected high-risk and advanced cases.<xref ref-type="bibr" rid="article-145334.r12">[12]</xref>&#x000a0;About 5% of prostate cancers are PSMA-negative, so PSMA-binding radioligands will not be helpful or therapeutic in these cases.<xref ref-type="bibr" rid="article-145334.r19">[19]</xref><xref ref-type="bibr" rid="article-145334.r20">[20]</xref><xref ref-type="bibr" rid="article-145334.r21">[21]</xref><xref ref-type="bibr" rid="article-145334.r22">[22]</xref>&#x000a0;</p>
        <p>Such tumors typically have a poor prognosis.&#x000a0;Fibroblast activation protein (FAP) is overexpressed in many solid tumors, including prostate cancer. Preliminary investigational studies suggest it may become a useful alternative PET tracer in PSMA-negative prostate cancer patients for both diagnostic imaging and theranostic treatment.<xref ref-type="bibr" rid="article-145334.r23">[23]</xref></p>
      </sec>
      <sec id="article-145334.s5" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>Commonly used radiopharmaceuticals and the scans used for imaging purposes are&#x000a0;summarised below.&#x000a0;Current good radiopharmaceutical practices should be considered when making and administering these agents. All pertinent regulations and guidelines should be followed in their creation, preparation, handling, storage, transport, dosing, and administration.<xref ref-type="bibr" rid="article-145334.r24">[24]</xref><xref ref-type="bibr" rid="article-145334.r25">[25]</xref><xref ref-type="bibr" rid="article-145334.r26">[26]</xref>&#x000a0;</p>
        <p>CT and MRI are essentially equivalent in the evaluation of lymph node metastases. However, MRI is superior to CT imaging with regard to contrast enhancement in the evaluation of prostatic and pelvic anatomy. Both imaging modalities identify bone metastases well.</p>
        <p><bold>F-18-FDG</bold> is a commonly used radioisotope scan for many malignancies, but it is not optimal or generally recommended for prostate cancer.<xref ref-type="bibr" rid="article-145334.r27">[27]</xref>&#x000a0;F-18-FDG is a glucose analog that accumulates in cells and tissues with increased metabolic activity.<xref ref-type="bibr" rid="article-145334.r28">[28]</xref> However, when used in prostate cancer, it demonstrates generally low overall sensitivity.<xref ref-type="bibr" rid="article-145334.r29">[29]</xref>&#x000a0;This is caused by the relatively slow rate of glucose metabolism in prostate cancer compared to other malignancies.</p>
        <p>Urinary excretion of the radioisotope can interfere with the imaging of prostatic lesions. Also, several benign conditions can cause false positives with increased F18-FDG uptake in the prostate, such as benign prostatic hyperplasia, prostatitis, and various cystic malformations.<xref ref-type="bibr" rid="article-145334.r27">[27]</xref><xref ref-type="bibr" rid="article-145334.r29">[29]</xref>&#x000a0;For all of these reasons and a lack of specific data showing a benefit, F-18-FDG scans are not currently recommended by the National Comprehensive Cancer Network (NCCN) for the routine staging of prostate cancer.</p>
        <p>
<bold>Radiopharmaceuticals for Bone Scan Imaging&#x000a0;</bold>
</p>
        <p><bold>Bone scans</bold> are designed to identify skeletal metastases in prostate cancer. The national comprehensive cancer network (NCCN) recommends an initial bone scan for patients at high risk for skeletal metastases (PSA equal or &#x0003e;20 ng/mL; clinical stage at least T2c; or Gleason 8, 9, or 10).<xref ref-type="bibr" rid="article-145334.r30">[30]</xref></p>
        <p>They are also indicated in evaluating patients at high risk for metastasis after radical prostatectomy surgery if PSA levels do not become undetectable or if subsequent PSA levels become detectable on at least 2&#x000a0;occasions.</p>
        <p>Bone scans may be considered in patients who become symptomatic, have an increasing PSA, or have a positive digital rectal examination after definitive radiation therapy. They can be used to monitor the response to androgen deprivation therapy, for which the NCCN recommends repeating the bone scan every 6 to 12 months. The NCCN recommends a bone scan interval of 8 to 12 weeks to monitor castrate-resistant prostate cancer.</p>
        <p>Ga-68-PSMA-11, F-18-piflufolastat&#x000a0;(DCFPyL), C-11-choline, and F-18-fluciclovine may all be considered to clarify equivocal results on initial bone scans.</p>
        <p>A separate bone scan is not required if a Ga-68 PSMA-11 or F-18 piflufolastat (DCFPyL) PSMA PET/CT scan is performed.</p>
        <p>
<bold>Tc-99m Diphosphonates (99mTc-MDP) Bone Scan</bold>
</p>
        <p>Gamma camera-based bone scans are widely available in clinical practice and have a long history of staging bone metastases in prostate cancer. Patients do not require specific preparation for this procedure. The imaging typically takes approximately 45 minutes, but patients require injection approximately&#x000a0;3 hours before scanning.</p>
        <p>The introduction of 3D fusion hybrid imaging with single photon emission computed tomography and computerized X-ray tomography (SPECT-CT) has improved the resolution and anatomic localization of the acquired images. To identify bone metastases with the traditional Tc-99m bone scan, PSA levels typically have to be 20 ng/mL or higher, while PET scans typically require only 0.2 ng/mL.</p>
        <list list-type="bullet">
          <list-item>
            <p>Indication:&#x000a0;Detection and evaluation of bone metastases utilizing increased bone turnover.</p>
          </list-item>
          <list-item>
            <p>Scanner Used:&#x000a0;Gamma camera/SPECT-CT.</p>
          </list-item>
          <list-item>
            <p>Tracer: [99m Tc] technetium hydroxy diphosphonate is the most commonly used tracer.</p>
          </list-item>
          <list-item>
            <p>Tracer Pharmacokinetics:&#x000a0;Diphosphonates&#x000a0;function as phosphate analogs that, through chemisorption, combine with crystalline hydroxyapatite in bone.</p>
          </list-item>
          <list-item>
            <p>Acquisition protocol
<list list-type="bullet"><list-item><p>Injected dose: 730-1110 MBq injected intravenously</p></list-item><list-item><p>Injection to imaging time: 2&#x000a0;to 4 hours</p></list-item><list-item><p>Protocol: whole body image acquisition with anterior and posterior projections</p></list-item><list-item><p>SPECT/CT of regions of interest</p></list-item><list-item><p>Reconstructions: performed utilizing iterative reconstructive methods [objective substitute expectation maximization (OSEM), maximum likelihood expectation maximization (MLEM)]</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Sensitivity: 79%</p>
          </list-item>
          <list-item>
            <p>Specificity: 86%</p>
          </list-item>
          <list-item>
            <p>Positive predictive value: 45%</p>
          </list-item>
          <list-item>
            <p>Negative predictive value: 96%<xref ref-type="bibr" rid="article-145334.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>FDA-approved for suspected bone metastases</p>
          </list-item>
        </list>
        <p>
<bold>[F-18] F-18-Sodium Fluoride Bone Scan</bold>
</p>
        <p>F-18-sodium fluoride&#x000a0;positron emission tomography (PET) has a high specificity and sensitivity for bone metastases.&#x000a0;This scan&#x000a0;has become a frequent replacement for conventional diphosphonate bone scans as PET/CT cameras become more common in clinical practice. Medical cyclotrons can produce f-18-sodium fluoride. The scans are more sensitive to bone turnover than diphosphonate scintigraphy, involve less uptake time, and offer 3D whole-body hybrid imaging with CT.</p>
        <p>Patients generally fast for 4 hours before intravenous tracer administration and are advised to stay hydrated before and during the uptake time post-injection.</p>
        <p>Whole body images with CT fusion help to identify and localize individual bone metastases in 3D volumes.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Indication: suspected bone metastases due to advanced prostate cancer; a replacement and upgrade for the traditional Tc-99 MDP bone scan.</p>
          </list-item>
          <list-item>
            <p>Scanner Used: PET-CT.</p>
          </list-item>
          <list-item>
            <p>Tracer Pharmacokinetics: uptake based on the chemisorption of fluoride ions on the surface of hydroxyapatite, which exchanges hydroxyl ions in the crystal to make fluorapatite.</p>
          </list-item>
          <list-item>
            <p>Acquisition protocol
<list list-type="bullet"><list-item><p>Injected dose: 1.5-3.7 MBq/kg with a max of 370 MBq doses for large patients</p></list-item><list-item><p>Radiopharmaceuticals: injected intravenously</p></list-item><list-item><p>Injection to imaging time: 30&#x000a0;to 45 minutes</p></list-item><list-item><p>Scan acquired: typically a whole-body image</p></list-item><list-item><p>CT protocol: 35 mA, 120 kVp, with a rotation time of 0.55 seconds, Pitch 0.85 with a FOV of 780 mm</p></list-item><list-item><p>PET protocol: 256 X 256 matrix, Zoom 1.0, 2&#x000a0;to 5 minutes/bed position scan duration; reconstruction should be performed via iterative-based methods with a setting of 2 iterations and 21 subsets.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Sensitivity and specificity: sensitivity - 77 to 94%, specificity - 92 to 99%.<xref ref-type="bibr" rid="article-145334.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Positive predictive value (PPV) for bone metastasis: 82 to 97%<xref ref-type="bibr" rid="article-145334.r32">[32]</xref><xref ref-type="bibr" rid="article-145334.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Equivalent to&#x000a0;F-18-PSMA piflufolastat (DCFPyL) for the detection of bony metastases.<xref ref-type="bibr" rid="article-145334.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>FDA-approved for suspected bone metastases only</p>
          </list-item>
          <list-item>
            <p>Recommended by the NCCN for bone metastases only</p>
          </list-item>
        </list>
        <p>
<bold>Radiopharmaceuticals for Prostate Cancer Imaging&#x000a0;</bold>
</p>
        <p>
<bold>[C-11] Carbon-11-Choline PET Scan</bold>
</p>
        <p>Choline has numerous nutritional functions. Prostate cancer cells have markedly increased choline uptake, which concentrates in these cells. Carbon-11 (C-11) radioisotope labeled choline was used for early detection of recurrent malignant disease but is not currently recommended for initial staging. Carbon-11 has a short half-life (20 minutes), requiring an on-site cyclotron, limiting its availability. F-18-fluorocholine PET/CT is more widely used in clinical practice due to its longer half-life. Ga-68 radioligands have a longer half-life and do not require a cyclotron on-site.<xref ref-type="bibr" rid="article-145334.r35">[35]</xref>&#x000a0;</p>
        <p>Choline-based scans are less sensitive than PSMA-binding radioligand imaging, and their indications have now been superseded in most nuclear medicine practices.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications: detecting recurrent disease and metastases&#x000a0;for biochemical recurrence or progression only.</p>
          </list-item>
          <list-item>
            <p>Scanner Used: PET-CT.</p>
          </list-item>
          <list-item>
            <p>Tracer pharmacokinetics: malignant prostate cells have higher kinase expression, increasing choline uptake and phosphatidylcholine concentrations; high phosphatidylcholine concentrations can be detected using radiotracer-tagged choline.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acquisition protocol&#x000a0;
<list list-type="bullet"><list-item><p>Injected dose: 350 MB</p></list-item><list-item><p>Injected intravenously</p></list-item><list-item><p>Injection to imaging time: 10 minutes.</p></list-item><list-item><p>Position: position patient&#x000a0;supine with the arms elevated above the head</p></list-item><list-item><p>Scan: cover from the head to mid-thigh level</p></list-item><list-item><p>CT protocol: 35 mA, 120 kVp, with a rotation time of 0.55 seconds; pitch is&#x000a0;0.85 with a FOV of 780 mm</p></list-item><list-item><p>PET protocol:&#x000a0;256 X 256 matrix, Zoom 1.0,&#x000a0;1.5 to 2.5 minutes/bed position scan duration; reconstruction should be performed via iterative-based methods with a setting of 2 iterations and 21 subsets</p></list-item><list-item><p>Attenuation correction: performed with the help of CT scan data</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Positive predictive value for biochemical recurrence: 53 to 96%.</p>
          </list-item>
          <list-item>
            <p>FDA-approved: biochemical recurrence or progression only.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recommended by the NCCN: biochemical recurrence or progression only.</p>
          </list-item>
        </list>
        <p>
<bold>[F-18] F-Fluciclovine (FACBC) PET Scan</bold>
</p>
        <p>F-18-fluciclovine is an analog of the amino acid leucine. Prostate cancer has increased amino acid transport and utilization, which can be seen in PET/CT imaging using this agent. F-18-fluciclovine also has increased uptake in osteoblastic and osteolytic lesions, giving it approximate equivalency to bone scintigraphy. This analog&#x000a0;has been shown to find more bone metastases than Tc-99m MDP bone scans and offers the advantage of finding tissue lesions as well.<xref ref-type="bibr" rid="article-145334.r36">[36]</xref>&#x000a0;</p>
        <p>However, it has relatively poor specificity for primary prostate cancer and nodal disease. F-18-fluciclovine has high sensitivity but low specificity and a moderate positive predictive value for recurrent involvement in the prostate bed. F-18-fluciclovine is superior to CT alone, In-111-Prostascint, and C-11-choline, plus its limited urinary excretion improves the visualization of lesions near the bladder. However, it is less sensitive than PSMA-binding tracers, and its indications have also been largely superseded in clinical practice. It is&#x000a0;FDA-approved for biochemical recurrence and progression but not for initial staging.&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications:&#x000a0;Detection of recurrent disease and metastases. Biochemical recurrence.</p>
          </list-item>
          <list-item>
            <p>Scanner Used: PET-CT.</p>
          </list-item>
          <list-item>
            <p>Tracer Pharmacokinetics: A leucine analog, F-18-fluciclovine, shows increased uptake in bone and metastases.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acquisition Protocol:
<list list-type="bullet"><list-item><p>The injected dose is 370 MB.</p></list-item><list-item><p>Injected intravenously.</p></list-item><list-item><p>Injection to imaging time is 3 to 5 minutes.</p></list-item><list-item><p>The patient should be positioned supine with the arms elevated above the head after the injection.</p></list-item><list-item><p>The injection should be given to the right arm.</p></list-item><list-item><p>The scan should cover from the head to mid-thigh level.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Correct Localization Rate for Biochemical Recurrence: 87%&#x02013;91%.</p>
          </list-item>
          <list-item>
            <p>FDA-Approved for Biochemical Recurrence or Progression only.</p>
          </list-item>
          <list-item>
            <p>Recommended by the NCCN for Biochemical Recurrence or Progression only.</p>
          </list-item>
        </list>
        <p>
<bold>PSMA-Binding Radionuclide Imaging</bold>
</p>
        <p>Ga-68 and F-18 labeled PSMA-binding radioligands have the advantage of high sensitivity and specificity for metastatic prostate cancer lesions. With increasing pathological grade and the onset of androgen independence, PSMA expression appears to increase. Therefore, a PSMA-radioligand scan can effectively show bone, lymph node, and visceral metastatic lesions and primary disease at the prostate gland or local recurrence. In addition, the possibility of in-house production of Ga-68 with the help of a Ga-68 generator makes it a practical choice in facilities without a cyclotron.</p>
        <p>Cyclotron-produced F-18 PSMA binding radioligands have shown equally high specificity for metastatic prostate lesions compared to the more commonly used Ga-68 agents. Overall, PSMA-based PET-CT imaging now plays an essential role in detecting metastatic prostate cancer. Generally, a PSA level greater than 0.2 ng/mL is needed for good results from a PSMA-based PET scan. PSMA imaging should ideally be performed starting antiandrogen hormonal therapy as imaging sensitivity may be affected.</p>
        <p>Ga-68-PSMA PET/CT is currently the gold standard for PSMA imaging in prostate cancer, providing high sensitivity and specificity for detecting and staging the disease. However, Ga-68-PSMA PET/CT may be unavailable, particularly in resource-limited settings. In these situations, Tc-99m-PSMA single-photon emission computed tomography/computed tomography (SPECT/CT) and Tc-99m methyl diphosphonate (Tc-99m MDP) bone scans are commonly used for staging.</p>
        <p>
<bold>[Ga-68] Ga-68-PSMA-11</bold>
</p>
        <p>Ga-68-PSMA-11 radioligands were first described in 2012 and are now the most widely used radioisotope tracer for prostate cancer PET imaging.<xref ref-type="bibr" rid="article-145334.r37">[37]</xref>&#x000a0;They can detect very small metastases or recurrences due to high binding affinity, rapid rate of intracellular accumulation, and rapid elimination from non-target tissues. Ga-68 PSMA is highly concentrated in the salivary and lacrimal glands with moderate uptake in the liver, spleen, bowel, and sympathetic ganglia and only minimal concentration in normal prostate cells. It is superior (greater sensitivity) to choline PET imaging for prostate cancer and can be used for both initial staging and biochemical recurrences.<xref ref-type="bibr" rid="article-145334.r38">[38]</xref><xref ref-type="bibr" rid="article-145334.r39">[39]</xref>&#x000a0;The kidneys excrete Ga-PSMA-11, which accumulates in the bladder and may obscure adjacent lesions.</p>
        <p>Ga-68 has a relatively short half-life (68 minutes). In-house generators for Ga-68 help mitigate the drawbacks of its short half-life.<xref ref-type="bibr" rid="article-145334.r1">[1]</xref> Current commercially available Ga-68 radioligands for PSMA imaging are Ga-68-PSMA-11 and Ga-68-PSMA-I&#x00026;T. Ga-PSMA-11 is the more commonly used in clinical practice.</p>
        <list list-type="bullet">
          <list-item>
            <p>Sensitivity: 40%.</p>
          </list-item>
          <list-item>
            <p>Specificity: 95% for nodal involvement.</p>
          </list-item>
          <list-item>
            <p>Positive Predictive Value for Biochemical Recurrence: 92%.</p>
          </list-item>
          <list-item>
            <p>The half-life is 68 minutes.</p>
          </list-item>
          <list-item>
            <p>Requires a local generator.</p>
          </list-item>
          <list-item>
            <p>FDA-Approved for initial staging and biochemical recurrence or progression.</p>
          </list-item>
          <list-item>
            <p>Scanner Used: PET-CT.</p>
          </list-item>
          <list-item>
            <p>Patient preparation: patients fast for 3-4 hours before injection and remain hydrated to improve target to background uptake and reduce radiation dose to the urinary bladder.</p>
          </list-item>
          <list-item>
            <p>Tracer Pharmacokinetics:&#x000a0;PSMA is present in almost all prostate adenocarcinomas, including primary tumors and metastatic lesions.
<list list-type="bullet"><list-item><p>PSMA is significantly overexpressed in hormone-refractory malignant lesions.</p></list-item><list-item><p>Radioligands are directed against the antigen's intracellular (necrotic or apoptotic cells) or extracellular (live cell) motifs.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Acquisition Protocol:&#x000a0;
<list list-type="bullet"><list-item><p>The injected dose is&#x000a0;1.8&#x000a0;to 2.2 MBq/Kg.</p></list-item><list-item><p>Injected intravenously.</p></list-item><list-item><p>Injection to imaging time is&#x000a0;60 minutes.</p></list-item><list-item><p>The patient should be positioned supine with the arms elevated above the head.</p></list-item><list-item><p>The scan should generally cover from the head to mid-thigh level.</p></list-item><list-item><p>CT protocol: 35 mA, 120 kVp, with a rotation time of 0.55 seconds, Pitch 0.85 with a FOV of 780 mm.</p></list-item><list-item><p>PET protocol:&#x000a0;256 X 256 matrix, zoom 1.0,&#x000a0;3 - 4 minutes/bed position scan duration, reconstruction should be performed via iterative-based methods with a setting of 2 iterations and 21 subsets.</p></list-item><list-item><p>Attenuation correction must be performed with the help of CT scan data.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>FDA-Approved for Initial Staging and Biochemical Recurrence or Progression.</p>
          </list-item>
          <list-item>
            <p>Recommended by the NCCN for Initial Staging and Biochemical Recurrence or Progression.</p>
          </list-item>
        </list>
        <p>
<bold>[F-18] F-18-PSMA piflufolastat (DCFPyL)</bold>
</p>
        <p>[F-18] F-PSMA radioligands have similar performance characteristics to Ga-68-PSMA-11 in PET scans for prostate cancer but have a longer half-life at 2 hours. F-18 can be easily produced in a regional cyclotron.<xref ref-type="bibr" rid="article-145334.r40">[40]</xref>&#x000a0;Two commercially available F-18 radioligands are available: [F-18] F-PSMA-DCFPyl and [F-18] F-PSMA-1007. [F-18] F-PSMA-1007 has non-urinary (hepatobiliary) excretion, while [F-18] F-PSMA-DCFPyL is rapidly cleared from the urinary tract. Therefore both agents have advantages over current Gallium-based agents, which are excreted in the urine, for detecting lesions adjacent to the bladder that may be obscured in scans using Ga-68.<xref ref-type="bibr" rid="article-145334.r1">[1]</xref><xref ref-type="bibr" rid="article-145334.r41">[41]</xref>&#x000a0;Additional tips, suggestions, procedural details, and interpretation assistance can be found in the published F-18-DCFPyL PET/CT guidelines.<xref ref-type="bibr" rid="article-145334.r42">[42]</xref><xref ref-type="bibr" rid="article-145334.r43">[43]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Sensitivity: 31 to 42%.</p>
          </list-item>
          <list-item>
            <p>Specificity: 96 to 99% for nodal metastasis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Correct Localization Rate (CLR): 85 to 87% for biochemical recurrence.</p>
          </list-item>
          <list-item>
            <p>The half-life is 2 hours.</p>
          </list-item>
          <list-item>
            <p>Produced by a regional cyclotron.</p>
          </list-item>
          <list-item>
            <p>Equivalent to the&#x000a0; F-18-Sodium Fluoride bone scan for the detection of skeletal metastases.<xref ref-type="bibr" rid="article-145334.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Overall, roughly equivalent to Ga-68-PSMA-11 PET scans.</p>
          </list-item>
          <list-item>
            <p>FDA-Approved for Initial Staging and Biochemical Recurrence.</p>
          </list-item>
          <list-item>
            <p>Recommended by the NCCN for Initial Staging and Biochemical Recurrence or Progression.</p>
          </list-item>
        </list>
        <p>
<bold>Tc-99m-PSMA Radioligands</bold>
</p>
        <p>PSMA-binding radioligands using technetium 99m are in clinical use for the staging of prostate cancer. Because they use the gamma emitter technetium 99m, they allow planar imaging and SPECT/CT in most nuclear medicine departments using a gamma camera.</p>
        <p>Ga-68-PSMA PET/CT reveals a considerably higher average number of lesions and is more effective in detecting prostatic bed lesions than Tc-99m-PSMA SPECT/CT. But at higher PSA levels (&#x0003e;4 ng/ml), Tc-99m-PSMA SPECT/CT still provides high overall detection rates for prostate cancer metastases, and there is no significant difference in the detection of lymph nodes or bony metastases.<xref ref-type="bibr" rid="article-145334.r44">[44]</xref>&#x000a0;</p>
        <p>When compared head-to-head, patients with a PSA &#x0003e;2.1 ng/mL showed consistent results between the two imaging modalities.<xref ref-type="bibr" rid="article-145334.r44">[44]</xref></p>
        <p>Tc-99m-PSMA SPECT/CT does not detect small lesions well, so it is not recommended in patients with small-volume disease.<xref ref-type="bibr" rid="article-145334.r45">[45]</xref>&#x000a0;The total cost is substantially less than a Ga-68-PSMA PET/CT scan, making it a cost-effective alternative with no discernible difference in cancer detection at higher PSA levels between the two imaging modalities.<xref ref-type="bibr" rid="article-145334.r45">[45]</xref></p>
        <p>In a prospective, comparative trial,&#x000a0;99m-Tc PSMA was found to be far superior to 99m-Tc-MDP SPECT/CT with regards to sensitivity, specificity, and PSA cutoff (2.6 ng/mL vs. 15 ng/mL) in detecting bone metastases.<xref ref-type="bibr" rid="article-145334.r46">[46]</xref></p>
        <p>Ga-68-PSMA PET/CT provides higher spatial resolution and has a higher sensitivity and specificity for detecting metastases, particularly in the early stages of the disease.&#x000a0;Although its sensitivity cannot match the positron-emitting PSMA radioligands in a PET/CT camera, Tc-99m-PSMA SPECT/CT offers an effective, valuable, cost-effective alternative to centers or patients without access to a PET/CT facility.<xref ref-type="bibr" rid="article-145334.r45">[45]</xref></p>
        <p>
<bold>Indium-111 Capromab Pendetide Imaging</bold>
</p>
        <p>Capromab pendetide radiolabeled with indium-111 (indium-111 capromab pendetide), formerly used for imaging prostate cancer, was approved by the US Food and Drug Administration (FDA) in 1996. Indium-111 capromab pendetide is presented here primarily for historical context as it has been supplanted by newer imaging tracers as outlined above.</p>
        <p>Indium-111 capromab pendetide comprises a monoclonal antibody that targets an intracellular prostate-specific membrane antigen (PSMA) glycoprotein and a radioisotope, indium 111, which emits gamma radiation that a gamma camera can detect. Indium-111 capromab pendetide is injected into the patient's bloodstream, and the monoclonal antibody binds to the PSMA. Since only intracellular PSMA is targeted,&#x000a0;the radiolabeled antibody&#x000a0;can only identify necrotic prostate cancer cells, dramatically limiting its sensitivity and usefulness.<xref ref-type="bibr" rid="article-145334.r47">[47]</xref>&#x000a0;The gamma radiation emitted by the indium 111 is detected by a gamma camera, which produces an image of the prostate and any cancerous lesions.<xref ref-type="bibr" rid="article-145334.r48">[48]</xref><xref ref-type="bibr" rid="article-145334.r49">[49]</xref>&#x000a0;</p>
        <p>The technical protocol for indium-111 capromab pendetide imaging involves several steps. Before the injection, the patient must fast for at least&#x000a0;4 hours. The imaging procedure takes place over&#x000a0;2 days, with the injection of indium-111 capromab pendetide on day&#x000a0;1 and imaging on day 2. On day 1, the patient is injected with the radiolabeled antibody, prepared in a sterile, pyrogen-free environment. The recommended dose is 5 mCi (millicuries) or 185 MBq for patients with a mass under 90 kg and 7 mCi/225 MBq for patients with a mass over 90 kg. After injection, the patient must remain still for at least 30 minutes to allow for the distribution of the radiopharmaceutical throughout the body.</p>
        <p>The patient is then monitored for adverse reactions, such as allergies or injection site reactions. The patient returns for imaging on the second day (24-hour delay). The patient is positioned on the gamma camera/SPECT-CT table, and images are acquired, including the whole body (anterior and posterior view) and SPECT-CT from head to mid-thigh.&#x000a0;</p>
        <p>Indium-111 capromab pendetide imaging has several significant drawbacks. One major limitation is its low sensitivity for detecting small tumors.&#x000a0;This radiolabeled antibody&#x000a0;can only detect tumors larger than 1 cm in size, which means that smaller tumors may be missed. This limitation is due to the limited spatial resolution of gamma cameras, which cannot detect the tiny amounts of radiation emitted from small tumors.</p>
        <p>Another limitation is its low specificity.&#x000a0;Furthermore, indium-111 capromab pendetide imaging is not recommended for patients with a rising prostate-specific antigen (PSA) level after radical prostatectomy or radiation therapy.&#x000a0;This imaging may detect residual prostate tissue or inflammation rather than cancerous lesions. In addition, the long half-life of the indium-111 radioisotope increases the radiation burden on the patient.&#x000a0;</p>
        <p>While indium-111 capromab pendetide imaging has been used for over&#x000a0;2 decades to image prostate cancer, it has major and significant limitations.&#x000a0;This&#x000a0;imaging is best used with other imaging modalities, such as MRI or CT, to improve its sensitivity and specificity.&#x000a0;Overall, the performance of the indium-111 capromab pendetide PSMA-based scan has been very disappointing, and the NCCN no longer recommends it.<xref ref-type="bibr" rid="article-145334.r35">[35]</xref><xref ref-type="bibr" rid="article-145334.r50">[50]</xref><xref ref-type="bibr" rid="article-145334.r51">[51]</xref><xref ref-type="bibr" rid="article-145334.r52">[52]</xref>&#x000a0;New radiopharmaceutical agents, such as PSMA-targeted positron emission tomography (PET) tracers, are now available. They are far superior and preferred due to their high&#x000a0;sensitivity and specificity for imaging prostate cancer.<xref ref-type="bibr" rid="article-145334.r35">[35]</xref></p>
        <p>
<bold>Tips for PSMA-PET Interpretation</bold>
</p>
        <p>PSMA-PET imaging is a highly sensitive imaging modality used to detect prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.&#x000a0;Here are some tips and guidance for radiologists to help them interpret Ga-68-PSMA imaging and identify false positives:</p>
        <list list-type="bullet">
          <list-item>
            <p>Understand the limitations of Ga-68 PSMA imaging: Ga-68 PSMA imaging is a highly sensitive modality, but it is not 100% specific. False positives can occur for various reasons, such as inflammation, benign prostatic hyperplasia, prostatitis, new (within 90 days of starting) hormonal therapy, or even normal physiological uptake. Radiologists should be aware of these limitations and interpret the imaging in the context of the patient's clinical history and other findings.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Be familiar with the normal distribution of Ga-68 PSMA uptake: Ga-68 PSMA uptake is commonly seen in the prostate gland, ureters, bladder, and salivary glands. Radiologists should be familiar with the normal distribution of Ga-68 PSMA uptake and recognize these structures on the imaging.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Using multimodality imaging to confirm suspicious findings: False positives on Ga-68 PSMA imaging can be confirmed using other imaging modalities, such as CT or MRI. Radiologists should use multimodality imaging to confirm suspicious findings and rule out false positives.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Look for uptake patterns: False positives on Ga-68 PSMA imaging can be identified by looking for uptake patterns that do not fit the typical distribution of PSMA expression. For example, diffuse or asymmetric prostate uptake in the prostate gland is more likely to indicate inflammation rather than malignancy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consider the clinical history: The patient's clinical history can provide valuable information to help identify false positives on Ga-68 PSMA-PET imaging. For example, a patient with a history of a recent biopsy, radiation therapy, trauma, or surgery may have increased PSMA uptake due to inflammation or healing without any active malignancy.<xref ref-type="bibr" rid="article-145334.r53">[53]</xref><xref ref-type="bibr" rid="article-145334.r54">[54]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The&#x000a0;Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) has published standards on the indications, technical procedures, and acquisition as well as interpretation guidance for multiple PSMA PET/CT scans for prostate cancer imaging which is highly recommended, particularly for facilities new to these modern, state-of-the-art scanning modalities.<xref ref-type="bibr" rid="article-145334.r55">[55]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Additional guidance and tips on interpreting PSMA-PET scans have been published and are available.<xref ref-type="bibr" rid="article-145334.r42">[42]</xref><xref ref-type="bibr" rid="article-145334.r56">[56]</xref><xref ref-type="bibr" rid="article-145334.r57">[57]</xref><xref ref-type="bibr" rid="article-145334.r58">[58]</xref><xref ref-type="bibr" rid="article-145334.r59">[59]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Challenges to PSMA-PET Interpretation</bold>
</p>
        <p>Interpreting radioisotope PSMA-PET scans can be challenging due to false positives, the "flare response," trapping of the tracer in nontargeted tissues, and urinary excretion, which interferes with visualization.<xref ref-type="bibr" rid="article-145334.r60">[60]</xref>&#x000a0;</p>
        <p>Short-term androgen deprivation therapy may increase PSMA expression leading to increased radioisotope concentrations, while long-term hormonal therapy reduces PSMA exposure and uptake.<xref ref-type="bibr" rid="article-145334.r60">[60]</xref></p>
        <p>An essential aspect of Ga-68-PSMA scans is the phenomenon of "flare," which can occur shortly after the injection of the radioactive tracer. "Flare" is a transient increase in PSMA uptake in the prostate, metastatic lesions, or elsewhere occurring during the first hour after the radioisotope injection. While the exact cause of the flare is not fully understood, it is thought to be related to an immune response triggered by the injection.</p>
        <p>There are several possible interpretations of "flare" on a Ga-68-PSMA scan.&#x000a0;Fare could indicate active prostate cancer as malignant cells rapidly take up PSMA and its attached radioactive isotope.&#x000a0;The transient increase&#x000a0;may also be a sign of a positive therapeutic response.</p>
        <p>Patients undergoing treatment for prostate cancer may experience an initial, transient increase in PSMA uptake, followed by a subsequent decrease. This indicates that the treatment is working to reduce tumor size and malignant cell activity. This is known as a "PSMA flare response" and is considered a positive indicator of treatment efficacy.&#x000a0;</p>
        <p>However, flare can occur even in patients who have previously undergone definitive treatment for prostate cancer and have no evidence of active malignant disease. Such false-positive results may occur in benign conditions with inflammation or a localized cellular immune response, such as in prostatitis, untreated urinary tract infections, after starting antiandrogen therapy, and bone healing after radiation therapy or trauma.<xref ref-type="bibr" rid="article-145334.r61">[61]</xref><xref ref-type="bibr" rid="article-145334.r62">[62]</xref>&#x000a0;For this reason, PET scans should not be performed any earlier than&#x000a0;3 months after the start of antiandrogen hormonal therapy.<xref ref-type="bibr" rid="article-145334.r62">[62]</xref>&#x000a0;</p>
        <p>The patient's clinical history and other imaging findings must be considered when interpreting a possible flare. Further evaluation and follow-up may be necessary to confirm the presence of cancer and determine the appropriate course of treatment.<xref ref-type="bibr" rid="article-145334.r63">[63]</xref></p>
        <p>Interpreting radioisotope-PSMA PET scans can be challenging due to false positives, the flare response, trapping of the tracer in nontargeted tissues, and urinary excretion, which interferes with visualization.<xref ref-type="bibr" rid="article-145334.r60">[60]</xref>&#x000a0;Short-term androgen deprivation therapy may increase PSMA expression leading to high radioisotope concentrations, while long-term hormonal therapy reduces PSMA exposure and uptake.<xref ref-type="bibr" rid="article-145334.r60">[60]</xref></p>
        <p>
<bold>Summary: PET-Based Radionuclide Imaging in Prostate Cancer</bold>
</p>
        <p>Only&#x000a0;2 PET tracers are FDA-approved and recommended by the National Comprehensive Cancer Network (NCCN) for use in the initial staging of prostate cancer for patients with suspected metastatic disease AND biochemical recurrence or progression.</p>
        <list list-type="bullet">
          <list-item>
            <p>[F-18] F-PSMA piflufolastat (DCFPyL)</p>
          </list-item>
          <list-item>
            <p>[Ga-68] Ga-PSMA-11</p>
          </list-item>
        </list>
        <p>Five PET tracers are FDA-Approved and recommended by the NCCN for use only in prostate cancer patients with biochemical recurrence or progression.</p>
        <list list-type="bullet">
          <list-item>
            <p>[C-11] C-Choline</p>
          </list-item>
          <list-item>
            <p>[F-18] F-Fluciclovine</p>
          </list-item>
          <list-item>
            <p>[F-18] F-PSMA piflufolastat (DCFPyL)</p>
          </list-item>
          <list-item>
            <p>[F-18] F-Sodium fluoride (alternative for a bone scan only)</p>
          </list-item>
          <list-item>
            <p>[Ga-68] Ga-PSMA</p>
          </list-item>
        </list>
        <p>
<bold>Targeted Radiopharmaceutical Therapy for Prostate Cancer (Theranostics)</bold>
</p>
        <p>Radiolabeled PSMA-binding agents can also be used for therapy. The branch of nuclear medicine where imaging radioligands demonstrate tissue that can be targeted with similar therapy radioligands is known as theranostics.</p>
        <p>The use of radioligands for therapy requires specialist knowledge and training. Such treatment should be performed only by qualified staff in a certified facility<bold>.</bold></p>
        <p>Theranostics for prostate cancer target PSMA overexpression to concentrate therapeutic radioligands to those specific locations.</p>
        <p>Although there has been an explosion of interest in treating prostate cancer with targeted radiopharmaceuticals and multiple trials are in progress, there is only a single proven indication that such therapy has been shown to improve survival.<xref ref-type="bibr" rid="article-145334.r64">[64]</xref>&#x000a0;The only currently approved indication for PSMA-binding radioligand therapy is in metastatic castrate-resistant prostate cancer (mCRPC) patients with PSMA-positive disease progressing after first-line taxane treatment or who cannot receive chemotherapy. (See Patient Selection for Lu-177-PSMA Treatment below.)</p>
        <p>Current radioligand therapies are typically better tolerated than chemotherapy.<xref ref-type="bibr" rid="article-145334.r65">[65]</xref>&#x000a0;Two large, prospective clinical trials (Thera-P and VISION) have shown comparable or improved outcomes with targeted radioligand treatment compared to standard-of-care therapies.<xref ref-type="bibr" rid="article-145334.r64">[64]</xref><xref ref-type="bibr" rid="article-145334.r66">[66]</xref><xref ref-type="bibr" rid="article-145334.r67">[67]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The Thera-P trial showed a higher PSA response and fewer grade 3 or 4 adverse events compared with cabazitaxel in men with metastatic castration-resistant prostate cancer.<xref ref-type="bibr" rid="article-145334.r66">[66]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The VISION trial demonstrated prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.<xref ref-type="bibr" rid="article-145334.r64">[64]</xref><xref ref-type="bibr" rid="article-145334.r67">[67]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Lutetium-177 Radioligand Therapy</bold>
</p>
        <p>The following factors and characteristics make Lu-177 the currently preferred radionuclide for PSMA-targeted therapeutic purposes:<xref ref-type="bibr" rid="article-145334.r65">[65]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The mean penetration range of &#x003b2;&#x02212; particles emitted by Lu-177 in soft tissue is 670 &#x003bc;m, and maximal tissue penetration is 2 mm, localizing cytotoxic radiation to target lesions and reducing non-target injury to adjacent, bystander areas.</p>
          </list-item>
          <list-item>
            <p>Lu-177 also emits low-energy &#x003b3;-rays during its decay (Gamma radiation), which allows scintigraphy with gamma cameras and subsequent dosimetry.</p>
          </list-item>
          <list-item>
            <p>Lu-177 has +3 oxidation states simplifying chemical bonds with targeting agents.</p>
          </list-item>
          <list-item>
            <p>Lu-177 has a long half-life (6.73 days), making it an easily transportable radionuclide and helpful in delivering radiation to the target tissue.<xref ref-type="bibr" rid="article-145334.r68">[68]</xref></p>
          </list-item>
        </list>
        <p>Current commercially available Lu-177 labeled PSMA ligands are [Lu-177] Lu-PSMA-617 and [Lu-177] Lu-PSMA-I&#x00026;T.&#x000a0;Other PSMA binding radioligands, in particular those using alpha emitter Actinium-225 [Ac-225], remain experimental but are seeing increasing interest.<xref ref-type="bibr" rid="article-145334.r69">[69]</xref><xref ref-type="bibr" rid="article-145334.r70">[70]</xref><xref ref-type="bibr" rid="article-145334.r71">[71]</xref></p>
        <p>
<bold>Patient Selection for Lu-177-PSMA Treatment</bold>
</p>
        <p>Patients are usually referred by their medical oncologist, radiation therapist, or urologist. In this rapidly changing area of oncology, it is suggested that nuclear medicine practitioners and other specialists who regularly take care of prostate cancer patients periodically check the latest NCCN guidelines and recommendations, as the indications for this therapy are changing rapidly.</p>
        <p>Patient suitability for treatment may require a multidisciplinary team assessment, but ultimately it is the nuclear medicine specialist who assumes primary responsibility for the final decision regarding patient suitability and education, treatment planning, response assessment, and management of treatment-related complications as well as&#x000a0;adverse effects.&#x000a0;</p>
        <p><bold>Current clinical indications</bold>&#x000a0;include metastatic, castrate-resistant, progressive prostate cancer following conventional systemic, taxane-based chemotherapy. (Patients who cannot take or tolerate the chemotherapy for any reason are also candidates.) The tumor must show adequate expression of PSMA on a baseline [Ga-68] Ga-PSMA PET/CT scan. In addition, patients should have a life expectancy of at least six months, adequate bone marrow and renal function without renal outflow obstruction, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.</p>
        <p>Diffuse bone marrow disease with a high risk of marrow failure will exclude patients from therapy.</p>
        <p>Most institutions also assess for the presence of active disease that does not express PSMA and is, therefore, unlikely to respond to this treatment. This is done by performing an FDG PET/CT scan before approving the patient for&#x000a0;[Lu-177] Lu-PSMA-617 radioligand therapy.&#x000a0;</p>
        <p>
<bold>Treatment Protocols for Lu-177-PSMA Therapy</bold>
</p>
        <p>Patients typically receive&#x000a0;4 to&#x000a0;6 treatment cycles at 6- to 8-week intervals. Administered doses may be scaled or adjusted due to disease burden, renal impairment, or after dosimetry testing, but a typical administration is 7.4 GBq (200 mCi).</p>
        <p>Patients spend up to 4 hours in the nuclear medicine department for therapy. They are discharged when their radiation levels fall to a safe level for other contacts, per local radiation safety regulations, and any&#x000a0;adverse effects have been assessed and managed. Treated patients must understand and follow strict radiation protection procedures for up to 7 days due to the half-life of Lu-177 and radiopharmaceutical retention.&#x000a0;</p>
        <p>Patients usually fast before treatment but with oral hydration. They receive intravenous hydration and antiemetics in the treatment facility before therapy administration. Measures to reduce radiation dose to PSMA expressing normal salivary glands may be applied.</p>
        <p>Infusions of Lu-177 radioligands are typically performed over 5 to 30 minutes. Therefore, monitoring vital signs pre- and post-infusion of [Lu-177] Lu-PSMA is required.</p>
        <p>Approximately 13% of patients experience serious adverse effects. Patients may suffer nausea both during and after treatment. Additionally, fatigue may develop in the days following therapy. Diarrhea and drowsiness are mentioned relatively commonly. Xerostomia due to physiologic PSMA expression by salivary glands and dry eyes due to PSMA expression by the lacrimal glands may occur and may be irreversible. Hematuria is occasionally reported. The most commonly reported&#x000a0;adverse effects are&#x000a0;fatigue (43%), dry mouth (39%), and anemia (32%).</p>
        <p>Following treatment, marrow suppression may occur, usually in patients with preceding marrow impairment, and should be carefully monitored. Renal function also requires monitoring, but renoprotective amino acid infusions are unnecessary for current PSMA therapies, unlike similar radioligand therapy with [Lu-177] Lu-dotatate, which is used for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.</p>
        <p>Imaging the gamma emissions from [Lu-177] Lu-PSMA radioligands following therapy can be performed using a gamma camera. Whole body and SPECT images allow subjective uptake assessment to target and non-target tissue. If required, multiple timepoint imaging can be performed for dosimetry.</p>
        <p>Treatment response may be assessed using the tenets of the prostate cancer workgroup (PCWG3) but should reasonably include PSA response, follow-up imaging at PSMA PET, and diagnostic CT. In addition, patient symptom response and tolerance of therapy should also be key factors in assessing treatment. Quantitative pain assessments and quality of life should be performed before, during, and after therapy.</p>
        <p>
<bold>Other PSMA Ligand Therapies</bold>
</p>
        <p>Radioisotopes emitting alpha particles are also used in cancer treatment. Alpha particles typically travel about&#x000a0;6 cell diameters, with minimal tissue penetration.<xref ref-type="bibr" rid="article-145334.r72">[72]</xref>&#x000a0;However, compared to other radionuclide therapies, they have high linear energy transfer within this range.<xref ref-type="bibr" rid="article-145334.r73">[73]</xref>&#x000a0;Alpha particles cause double-strand damage to DNA within the nucleus, and cluster breaks independent of oxygenation and active cellular reproduction processes, in contrast to the single-strand damage of the beta-emitting Lu-177 radioligands, which is less likely to cause cell death but has a greater range.<xref ref-type="bibr" rid="article-145334.r74">[74]</xref>&#x000a0;</p>
        <p>The alpha emitter Actinium-225 [Ac-225] application is increasing in radionuclide-based therapies. PSMA-binding radioligands of Ac-225 have been assessed in advanced metastatic castrate-resistant prostate cancer, which is Lu-177 resistant, with some early success.<xref ref-type="bibr" rid="article-145334.r75">[75]</xref>&#x000a0;Xerostomia is common, and hematologic side effects may limit or stop therapy.<xref ref-type="bibr" rid="article-145334.r75">[75]</xref>&#x000a0;</p>
        <p>Tandem therapy (using both Lu-177 and Ac-225 radioligands synchronously or serially) and other applications of Ac-225 radioligands in prostate cancer are currently under investigation.<xref ref-type="bibr" rid="article-145334.r76">[76]</xref><bold>&#x000a0;</bold></p>
        <p>Targeted &#x003b1;-therapy using astatine (211-At)-labeled PSMA appears promising in animal models for treating metastatic castration-resistant prostate cancer. Astatine has a half-life of 7.2 hours and can be produced by 30-MeV cyclotrons.<xref ref-type="bibr" rid="article-145334.r77">[77]</xref></p>
        <p>Multimodal radiobioconjugates of magnetic nanoparticles labeled with 44-Sc and 47-Sc (scandium) for theranostic use in prostate cancer are also being studied experimentally.<xref ref-type="bibr" rid="article-145334.r78">[78]</xref></p>
        <p>
<bold>Other Nuclear Medicine Therapies in Prostate Cancer</bold>
</p>
        <p>Beta-emitting radioisotopes samarium-153 [Sm-153] and strontium-89 [Sr-89] are used to manage pain from bone metastases in prostate and other cancers. [Sr-89] is administered as chloride salt and [Sm-153] as an EDTMP complex. Both bind to sites of osteogenesis, usually indicated by the uptake of other bone-seeking radiopharmaceuticals in imaging bone scans.</p>
        <p>Metastasis irradiation is an indirect effect of osteoblastic bone turnover rather than due to direct binding to tumor cells. Both agents have shown effective pain relief from bone metastases in clinical trials, but unfortunately, they provide no survival advantage. Both agents exhibit myelotoxicity as the dose-limiting factor.</p>
        <p>Radium-223 (Ra-223) is an alpha-emitting radioisotope given to people with osteoblastic metastases from prostate cancer.&#x000a0;This isotope has the same benefits and limitations similar to other alpha emitters used in nuclear medicine therapy.&#x000a0;Ra-223 is not only effective in the relief of pain from bone metastases but also shows a survival benefit compared to beta-emitting agents. Concomitant use with&#x000a0;denosumab or zoledronic acid is recommended and will not interfere with the survival benefits of radium-223.</p>
        <p>Radium-223 has not been shown to provide a survival benefit in patients with&#x000a0;visceral metastases or bulky nodal disease (&#x0003e;3&#x02013;4 cm). The isotope is also limited by myelotoxicity, despite a theoretical advantage compared to the longer path lengths of the beta-emitting agents. Radium-223 should not be used in combination with myelosuppressive chemotherapy or docetaxel. It can also cause an increased risk of fractures if used with abiraterone.</p>
        <p>Before starting treatment with radium-223, the patient must have a neutrophil count of&#x000a0;&#x02265;1,500,000/mL, a platelet count of &#x02265;100,000,000/mL, and a hemoglobin level of &#x02265;10 g/dL. The neutrophil count must be&#x000a0;&#x02265;1,000,000/mL for subsequent doses with a platelet count of&#x000a0;&#x02265;50,000,000/mL. If these hematological minimums cannot be reached after the Radium-223 therapy has been discontinued for&#x000a0;8 weeks, the treatment should be discontinued.</p>
        <p>Other bone-seeking agents in clinical and experimental use include radioisotopes of rhenium and [Lu-177] Lu-EDTMP.</p>
        <p>
<bold>Summary of Principal Therapeutic Targeted Radiopharmaceuticals </bold>
</p>
        <p><bold>Lutetium-177</bold>&#x000a0;([Lu-177] Lu-PSMA-617, [Lu-177] Lu-PSMA-I&#x00026;T)</p>
        <list list-type="bullet">
          <list-item>
            <p>Physical characteristics
<list list-type="bullet"><list-item><p>Beta and gamma emitters</p></list-item><list-item><p>497 keV Beta max</p></list-item><list-item><p>113 (6.6%) and 210 (11%) keV of gamma radiation</p></list-item><list-item><p>Half-life of 6.73 days</p></list-item><list-item><p>Mean penetration of beta particles&#x000a0;- 670 microns</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Actinium-225</bold>&#x000a0;([Ac-225] Ac-PSMA-617,&#x000a0;[Ac-225] Ac-PSMA-I&#x00026;T)</p>
        <list list-type="bullet">
          <list-item>
            <p>Physical characteristics
<list list-type="bullet"><list-item><p>Alpha emitter</p></list-item><list-item><p>Limited beta and gamma emitter</p></list-item><list-item><p>410 keV alpha&#x000a0;energy</p></list-item><list-item><p>Half-life of 9.920 days<xref ref-type="bibr" rid="article-145334.r79">[79]</xref></p></list-item><list-item><p>Minimal tissue penetration</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Radium-223</bold>&#x000a0;([Ra-223] Ra-Chloride)</p>
        <list list-type="bullet">
          <list-item>
            <p>Physical characteristics
<list list-type="bullet"><list-item><p>Alpha emitter</p></list-item><list-item><p>667 Mev/decay total alpha energy</p></list-item><list-item><p>Half-life&#x000a0;of 11.43 days</p></list-item><list-item><p>Mean range of penetration in soft tissue&#x000a0;- 43 microns<xref ref-type="bibr" rid="article-145334.r80">[80]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Strontium-89</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Physical characteristics
<list list-type="bullet"><list-item><p>Beta emitter</p></list-item><list-item><p>Average beta energy 1.46 Mev</p></list-item><list-item><p>Half-life&#x000a0;of 50.5 days</p></list-item><list-item><p>Mean range of penetration in soft tissue&#x000a0;- 2.4 mm<xref ref-type="bibr" rid="article-145334.r81">[81]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Samarium-153</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Physical characteristics
<list list-type="bullet"><list-item><p>Beta emitter</p></list-item><list-item><p>Average beta energy 0.58 Mev</p></list-item><list-item><p>Half-life of 1.93 days</p></list-item><list-item><p>Mean range of penetration in soft tissue - 0.6 microns<xref ref-type="bibr" rid="article-145334.r82">[82]</xref><xref ref-type="bibr" rid="article-145334.r83">[83]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>More Radioligand Diagnostic and Therapeutic Options&#x000a0;</bold>
</p>
        <p>Experimentally, PSMA PET/CT has improved the accuracy of staging prostate biopsies.<xref ref-type="bibr" rid="article-145334.r84">[84]</xref><xref ref-type="bibr" rid="article-145334.r85">[85]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>PSMA-based PET studies can be helpful with MRI scans in evaluating questionable PIRADS 3 lesions and selected PIRADS 1 or 2 nodules.<xref ref-type="bibr" rid="article-145334.r19">[19]</xref><xref ref-type="bibr" rid="article-145334.r86">[86]</xref><xref ref-type="bibr" rid="article-145334.r87">[87]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hybrid PET/MRI cameras can improve the detection rate of extracapsular extension, seminal vesicle involvement, infiltration of the neurovascular bundle, and neighboring organ spread when assessing primary disease.<xref ref-type="bibr" rid="article-145334.r86">[86]</xref><xref ref-type="bibr" rid="article-145334.r88">[88]</xref><xref ref-type="bibr" rid="article-145334.r89">[89]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>PSMA-based immunotherapy, without radiation, is also being investigated.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>These studies include immune checkpoint inhibitors, chimeric antigen receptors, bispecific antibodies, and tri-specific T-cell activating molecules.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145334.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Modern radionuclide PET scan imaging and targeted radiopharmaceutical therapy can significantly change management decisions in over 50% of prostate cancer patients tested and offer substantially improved survival in those with advanced disease.<xref ref-type="bibr" rid="article-145334.r90">[90]</xref><xref ref-type="bibr" rid="article-145334.r91">[91]</xref>&#x000a0;</p>
        <p>PSMA PET imaging is superior to CT imaging and standard bone scans for the staging of prostate cancer.<xref ref-type="bibr" rid="article-145334.r92">[92]</xref><xref ref-type="bibr" rid="article-145334.r93">[93]</xref></p>
        <p>PSMA-based imaging should be&#x000a0;performed before antiandrogen hormonal therapy is started (NCCN recommendation.)</p>
        <p>Ga-68-PSMA-11 and F-18-piflufolastat (DCFPyL) PET imaging have each demonstrated higher sensitivity than C-11 choline or F-18 fluciclovine PET imaging, especially at very low PSA levels.</p>
        <p>No separate bone scan is necessary when performing a Ga-68-PSMA-11 or F-18 piflufolastat&#x000a0;(DCFPyL) PSMA PET/CT scan.</p>
        <p>Tc-99m-PSMA single-photon emission computed tomography/computed tomography (SPECT/CT) can be a cost-effective alternative to more expensive PET scans.</p>
        <p>Various new imaging techniques are now available to evaluate better each patient's prostate cancer staging, course, and progress.</p>
        <p>Nuclear medicine-based diagnostic imaging and therapeutics can significantly affect treatment planning, therapeutic decisions, quality of life, and overall survival.</p>
      </sec>
      <sec id="article-145334.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Updated standards&#x000a0;and guidelines covering the&#x000a0;indications, technical procedures, proper handling of radiotracers, and interpretation of PSMA PET/CT scans for prostate cancer are available for multiple PSMA radioligands.<xref ref-type="bibr" rid="article-145334.r55">[55]</xref></p>
        <p>Initiating a new radioligand therapy center requires the interest, diligence, and cooperation of an interprofessional team, including all the involved clinical services and administrative input and support. An organizational plan that clearly delineates the responsibilities of each clinical team member in covering all of the required tasks is essential. Scheduling services, reimbursement, care coordination, patient education, counseling, safety considerations, and financial support are also necessary for establishing a first-class center.<xref ref-type="bibr" rid="article-145334.r94">[94]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Every patient diagnosed with prostate cancer faces unique difficulties, concerns, and worries related to understanding the diagnosis, staging, prognosis, and treatment of their disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients and their families receive abundant information about prostate cancer from multiple sources, some of which may be conflicting or outdated. They may find much of this information confusing and challenging to understand fully.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients and families who require extra time or help with communication, teaching, or understanding should receive appropriate, comprehensive, and knowledgeable counseling.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Several imaging techniques can be used to figure out the stage and progression of the disease.&#x000a0;To get the best results, each team member must interact with patients effectively and consistently about the available imaging options.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Because a thorough and consistent approach is necessary, an informed multidisciplinary team is critical when discussing all aspects of disease management, prognosis, and imaging modalities with patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Every staff member plays an essential role in communicating, educating, and caring for these patients, who are often quite physically and emotionally fragile, to achieve optimal outcomes.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145334.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145334&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145334">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/145334/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=145334">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-145334.s9">
        <fig id="article-145334.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Treatment mechanism of 177-Lu-PSMA Madhusudan Vyas</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Capture-2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145334.s10">
        <fig id="article-145334.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Treatment protocol of Lu-177-PSMA based infusion for mCRPC Contributed by Madhusudan Vyas</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Capture-1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145334.s11">
        <fig id="article-145334.image.f3" position="float" orientation="portrait">
          <caption>
            <p>A pre and post Lu-177-PSMA therapy 68-Ga-PSMA PET-CT scan showing positive otcomes Contributed by Madhusudan Vyas</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Capture-4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145334.s12">
        <fig id="article-145334.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Positive treatment outcome in a hepatic metastatic lesion post 4 cycles of 177-Lu-PSMA treatment Contributed by Madhusudan Vyas</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Capture-5" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145334.s13">
        <fig id="article-145334.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Various Steps of Lu-177-PSMA treatment Contributed by Madhusudan Vyas</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Capture-3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-145334.s14">
        <title>References</title>
        <ref id="article-145334.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaewput</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vinjamuri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>May</month>
            <day>12</day>
            <volume>11</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">35628867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sapra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Cancer Screening</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32310541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Prostate Cancer.</article-title>
            <source>World J Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>63</fpage>
            <page-range>63-89</page-range>
            <pub-id pub-id-type="pmid">31068988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>US Preventive Services Task Force</collab>
              <name>
                <surname>Grossman</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Bibbins-Domingo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Caughey</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Doubeni</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ebell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epling</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Krist</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kubik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landefeld</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mangione</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>May</month>
            <day>08</day>
            <volume>319</volume>
            <issue>18</issue>
            <fpage>1901</fpage>
            <page-range>1901-1913</page-range>
            <pub-id pub-id-type="pmid">29801017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farolfi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Castellucci</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Theragnostics in prostate cancer.</article-title>
            <source>Q J Nucl Med Mol Imaging</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>333</fpage>
            <page-range>333-341</page-range>
            <pub-id pub-id-type="pmid">35133097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Salvarese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carpanese</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gobbi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Melendez-Alafort</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bolzati</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Review on the Current State and Future Perspectives of [<sup>99m</sup>Tc]Tc-Housed PSMA-i in Prostate Cancer.</article-title>
            <source>Molecules</source>
            <year>2022</year>
            <month>Apr</month>
            <day>19</day>
            <volume>27</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">35565970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Baradhi</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <chapter-title>Benign Prostatic Hyperplasia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">32644346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bolla</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <chapter-title>Anatomy, Abdomen and Pelvis, Prostate</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">31082031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Silva</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alcorn</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Jun</month>
            <day>15</day>
            <volume>14</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">35740617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Wu</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>De Cicco</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <chapter-title>Anatomy, Abdomen and Pelvis, Male Genitourinary Tract</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">32965962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pletcher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prostate organogenesis.</article-title>
            <source>Development</source>
            <year>2022</year>
            <month>Jun</month>
            <day>15</day>
            <volume>149</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">35726824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haug</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Aug</month>
            <day>02</day>
            <volume>14</volume>
            <issue>15</issue>
            <pub-id pub-id-type="pmid">35954432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iagaru</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aparici</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.</article-title>
            <source>Nanotheranostics</source>
            <year>2022</year>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-117</page-range>
            <pub-id pub-id-type="pmid">34976584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koziorowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ballinger</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Theragnostic radionuclides: a clinical perspective.</article-title>
            <source>Q J Nucl Med Mol Imaging</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-314</page-range>
            <pub-id pub-id-type="pmid">34881851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;vels</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Heesakkers</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Adang</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Jager</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Strum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoogeveen</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Severens</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Barentsz</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.</article-title>
            <source>Clin Radiol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-95</page-range>
            <pub-id pub-id-type="pmid">18325358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suh</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Shinagare</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Westenfield</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ramaiya</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Van den Abbeele</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis.</article-title>
            <source>Clin Radiol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-167</page-range>
            <pub-id pub-id-type="pmid">28958581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hofer</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hautmann</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kuefer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.</article-title>
            <source>Hum Pathol</source>
            <year>2007</year>
            <month>May</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>696</fpage>
            <page-range>696-701</page-range>
            <pub-id pub-id-type="pmid">17320151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chodak</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>172</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-6</page-range>
            <pub-id pub-id-type="pmid">15201753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eiber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weirich</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Holzapfel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Souvatzoglou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rauscher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wester</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwaiger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Simultaneous <sup>68</sup>Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>829</fpage>
            <page-range>829-836</page-range>
            <pub-id pub-id-type="pmid">26795686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannweiler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amersdorfer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trajanoski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Terrett</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mehes</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.</article-title>
            <source>Pathol Oncol Res</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-72</page-range>
            <pub-id pub-id-type="pmid">18802790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rauscher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Souvatzoglou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weirich</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wester</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Heck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000fc;bler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Schwaiger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eiber</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.</article-title>
            <source>J Urol</source>
            <year>2016</year>
            <month>May</month>
            <volume>195</volume>
            <issue>5</issue>
            <fpage>1436</fpage>
            <page-range>1436-1443</page-range>
            <pub-id pub-id-type="pmid">26682756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fendler</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Wenter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thierfelder</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Zach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stief</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bartenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kirchner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gildehaus</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Gratzke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.</article-title>
            <source>J Nucl Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>11</issue>
            <fpage>1720</fpage>
            <page-range>1720-1725</page-range>
            <pub-id pub-id-type="pmid">27261520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laudicella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spataro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Croc&#x000e8;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giacoppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dav&#x000ec;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Librando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nicocia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rappazzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Celesti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garraffa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bauckneht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Minutoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baldari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2023</year>
            <month>Mar</month>
            <day>19</day>
            <volume>13</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">36980482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>YX</given-names>
              </name>
            </person-group>
            <article-title>Current state of prostate-specific membrane antigen PET/CT imaging-targeted biopsy techniques for detection of clinically significant prostate cancer.</article-title>
            <source>J Med Imaging Radiat Oncol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>776</fpage>
            <page-range>776-780</page-range>
            <pub-id pub-id-type="pmid">34914195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000f6;der</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Knopp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Tawab-Amiri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Beach</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>SA</given-names>
              </name>
              <collab>Members of the Working Group</collab>
              <name>
                <surname>Shankar</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.</article-title>
            <source>J Clin Oncol</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>40</volume>
            <issue>13</issue>
            <fpage>1500</fpage>
            <page-range>1500-1505</page-range>
            <pub-id pub-id-type="pmid">35015566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.</article-title>
            <source>Int J Cancer</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>152</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-50</page-range>
            <pub-id pub-id-type="pmid">35751420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Teh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pitfalls of FDG-PET in the prostate for the surgical oncologist.</article-title>
            <source>Urol Case Rep</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>33</volume>
            <fpage>101262</fpage>
            <pub-id pub-id-type="pmid">32489895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hess</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blomberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>H&#x000f8;ilund-Carlsen</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Alavi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The pivotal role of FDG-PET/CT in modern medicine.</article-title>
            <source>Acad Radiol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-49</page-range>
            <pub-id pub-id-type="pmid">24439337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawrentschuk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Positron emission tomography and molecular imaging of the prostate: an update.</article-title>
            <source>BJU Int</source>
            <year>2006</year>
            <month>May</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>923</fpage>
            <page-range>923-31</page-range>
            <pub-id pub-id-type="pmid">16643472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Amico</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Whittington</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malkowicz</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Broderick</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Renshaw</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beard</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.</article-title>
            <source>JAMA</source>
            <year>1998</year>
            <month>Sep</month>
            <day>16</day>
            <volume>280</volume>
            <issue>11</issue>
            <fpage>969</fpage>
            <page-range>969-74</page-range>
            <pub-id pub-id-type="pmid">9749478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Joseph Simeone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Taneja</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Torriani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bredella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the diagnostic accuracy of 99&#x02009;m-Tc-MDP bone scintigraphy and 18&#x02009;F-FDG PET/CT for the detection of skeletal metastases.</article-title>
            <source>Acta Radiol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-65</page-range>
            <pub-id pub-id-type="pmid">25533313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broos</surname>
                <given-names>WAM</given-names>
              </name>
              <name>
                <surname>van der Zant</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Wondergem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knol</surname>
                <given-names>RJJ</given-names>
              </name>
            </person-group>
            <article-title>Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma.</article-title>
            <source>Nucl Med Commun</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>325</fpage>
            <page-range>325-333</page-range>
            <pub-id pub-id-type="pmid">29351123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e9;nard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harsini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zukotynski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abikhzer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Turcotte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cossette</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Metser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Romsa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Soucy</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Eigl</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krauze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burrell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tardif</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Intra-individual comparison of <sup>18</sup>F-sodium fluoride PET-CT and <sup>99m</sup>Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>1499</fpage>
            <page-range>1499-1507</page-range>
            <pub-id pub-id-type="pmid">36343655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowe</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Trock</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DiGianvittorio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleiler</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Abdallah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pienta</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Gorin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pomper</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Prospective Comparison of PET Imaging with PSMA-Targeted <sup>18</sup>F-DCFPyL Versus Na<sup>18</sup>F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.</article-title>
            <source>J Nucl Med</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-188</page-range>
            <pub-id pub-id-type="pmid">31451492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Soon-Sutton</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>R I</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sajjad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Skelton</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">29261872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Macapinlac</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.</article-title>
            <source>Nucl Med Commun</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>9</issue>
            <fpage>940</fpage>
            <page-range>940-946</page-range>
            <pub-id pub-id-type="pmid">31343613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bauder-W&#x000fc;st</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hull</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>W&#x000e4;ngler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Haberkorn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Eisenhut</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.</article-title>
            <source>Bioconjug Chem</source>
            <year>2012</year>
            <month>Apr</month>
            <day>18</day>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>688</fpage>
            <page-range>688-97</page-range>
            <pub-id pub-id-type="pmid">22369515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Afshar-Oromieh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zechmann</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Malcher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eisenhut</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linhart</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Holland-Letz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hadaschik</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Giesel</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Debus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haberkorn</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-20</page-range>
            <pub-id pub-id-type="pmid">24072344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morigi</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hruby</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fogarty</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jagavkar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kneebone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hickey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tarlinton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Emmett</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.</article-title>
            <source>J Nucl Med</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>8</issue>
            <fpage>1185</fpage>
            <page-range>1185-90</page-range>
            <pub-id pub-id-type="pmid">26112024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dietlein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuhnert</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stockter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schom&#x000e4;cker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dietlein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zlatopolskiy</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Krapf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Richarz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drzezga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neumaier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.</article-title>
            <source>Mol Imaging Biol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>575</fpage>
            <page-range>575-84</page-range>
            <pub-id pub-id-type="pmid">26013479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giesel</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Hadaschik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cardinale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Radtke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vinsensia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lehnert</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kesch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tolstov</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grabe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Duensing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neels</surname>
                <given-names>OC</given-names>
              </name>
              <name>
                <surname>Mier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Haberkorn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kopka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kratochwil</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>678</fpage>
            <page-range>678-688</page-range>
            <pub-id pub-id-type="pmid">27889802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guti&#x000e9;rrez Cardo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Vallejo Casas</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Garz&#x000f3;n</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tirado Hospital</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Medina L&#x000f3;pez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Freire Mac&#x000ed;as</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez Fern&#x000e1;ndez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title><sup>18</sup>F-DCFPyL PET/CT guidelines.</article-title>
            <source>Rev Esp Med Nucl Imagen Mol (Engl Ed)</source>
            <year>2023</year>
            <season>May-Jun</season>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-208</page-range>
            <pub-id pub-id-type="pmid">36878314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowe</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Voter</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Zukotynski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Pomper</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Gorin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Solnes</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.</article-title>
            <source>Can J Urol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>11432</fpage>
            <page-range>11432-11437</page-range>
            <pub-id pub-id-type="pmid">36779950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albalooshi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Al Sharhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bagheri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Miyanath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Muhasin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zakavi</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Direct comparison of <sup>99m</sup>Tc-PSMA SPECT/CT and <sup>68</sup>Ga-PSMA PET/CT in patients with prostate cancer.</article-title>
            <source>Asia Ocean J Nucl Med Biol</source>
            <year>2020</year>
            <season>Winter</season>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">32064277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawal</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Ankrah</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Mokgoro</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Vorster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sathekge</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.</article-title>
            <source>Prostate</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>77</volume>
            <issue>11</issue>
            <fpage>1205</fpage>
            <page-range>1205-1212</page-range>
            <pub-id pub-id-type="pmid">28649735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Head-to-head comparison of <sup>99m</sup>Tc-PSMA and <sup>99m</sup>Tc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Sep</month>
            <day>26</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>15993</fpage>
            <pub-id pub-id-type="pmid">36163353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gusman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aminsharifi</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Clemenshaw</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Review of <sup>18</sup>F-Fluciclovine PET for Detection of Recurrent Prostate Cancer.</article-title>
            <source>Radiographics</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>822</fpage>
            <page-range>822-841</page-range>
            <pub-id pub-id-type="pmid">31059396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sengupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Asha Krishnan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chattopadhyay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chelvam</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.</article-title>
            <source>Cancer Rep (Hoboken)</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>e1169</fpage>
            <pub-id pub-id-type="pmid">32721116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Schild</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ezzell</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Roarke</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2011</year>
            <month>Nov</month>
            <day>15</day>
            <volume>81</volume>
            <issue>4</issue>
            <fpage>e423</fpage>
            <page-range>e423-9</page-range>
            <pub-id pub-id-type="pmid">21477947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morigi</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DE Nunzio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prostate specific membrane antigen positron emission tomography/computed tomography and staging high risk prostate cancer: a non-systematic review of high clinical impact literature.</article-title>
            <source>Minerva Urol Nephrol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-41</page-range>
            <pub-id pub-id-type="pmid">32550630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koschel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.</article-title>
            <source>Curr Opin Urol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>569</fpage>
            <page-range>569-577</page-range>
            <pub-id pub-id-type="pmid">31567440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herlemann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wenter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kretschmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thierfelder</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bartenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gildehaus</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Stief</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Gratzke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fendler</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title><sup>68</sup>Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>553</fpage>
            <page-range>553-557</page-range>
            <pub-id pub-id-type="pmid">26810345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qin</surname>
                <given-names>ZQ</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>The performance of <sup>18</sup>F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis.</article-title>
            <source>Asian J Androl</source>
            <year>2022</year>
            <season>Jul-Aug</season>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <page-range>373-379</page-range>
            <pub-id pub-id-type="pmid">34747721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Gherlinzoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lauria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Emiliani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tabanelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intensive chemotherapy regimen in high-grade non Hodgkin's lymphomas.</article-title>
            <source>Tumori</source>
            <year>1987</year>
            <month>Apr</month>
            <day>30</day>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-6</page-range>
            <pub-id pub-id-type="pmid">3576707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fendler</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Eiber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beheshti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bomanji</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Calais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ceci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giesel</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Goffin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haberkorn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jacene</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kopka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lindenberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mottaghy</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Oprea-Lager</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Piert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;der</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wester</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>1466</fpage>
            <page-range>1466-1486</page-range>
            <pub-id pub-id-type="pmid">36604326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pomykala</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lalumera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Positive Prostate-specific Membrane Antigen Findings: How To Interpret Them.</article-title>
            <source>Eur Urol Oncol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-115</page-range>
            <pub-id pub-id-type="pmid">36428201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murad</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kulanthaivelu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Veit-Haibach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Metser</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Standardized classification schemes in reporting oncologic PET/CT.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>1051309</fpage>
            <pub-id pub-id-type="pmid">36777163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phelps</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Harmon</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mena</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lindenberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Citrin</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dahut</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Gulley</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Choyke</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Turkbey</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Predicting Outcomes of Indeterminate Bone Lesions on <sup>18</sup>F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.</article-title>
            <source>J Nucl Med</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-401</page-range>
            <pub-id pub-id-type="pmid">36265908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kase</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Copland</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Parent</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Mar</month>
            <day>08</day>
            <volume>14</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">35326513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Galante</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Haroon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Afaq</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bomanji</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adeleke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kasivisvanathan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.</article-title>
            <source>Nat Rev Urol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>475</fpage>
            <page-range>475-493</page-range>
            <pub-id pub-id-type="pmid">35789204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messiou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>deSouza</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Imaging metastatic bone disease from carcinoma of the prostate.</article-title>
            <source>Br J Cancer</source>
            <year>2009</year>
            <month>Oct</month>
            <day>20</day>
            <volume>101</volume>
            <issue>8</issue>
            <fpage>1225</fpage>
            <page-range>1225-32</page-range>
            <pub-id pub-id-type="pmid">19789531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bavbek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kordan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tilki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Esen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer.</article-title>
            <source>Eur Urol Focus</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>596</fpage>
            <page-range>596-605</page-range>
            <pub-id pub-id-type="pmid">36842919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malaspina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ettala</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tolvanen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rajander</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eskola</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bostr&#x000f6;m</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kemppainen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Flare on [<sup>18</sup>F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-na&#x000ef;ve metastatic prostate cancer patients.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>613</fpage>
            <page-range>613-621</page-range>
            <pub-id pub-id-type="pmid">36161511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sartor</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>de Bono</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Fizazi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rahbar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tagawa</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Nordquist</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Vaishampayan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>El-Haddad</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Armour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Contreras</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>DeSilvio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kpamegan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gericke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messmann</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>BJ</given-names>
              </name>
              <collab>VISION Investigators</collab>
            </person-group>
            <article-title>Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>16</day>
            <volume>385</volume>
            <issue>12</issue>
            <fpage>1091</fpage>
            <page-range>1091-1103</page-range>
            <pub-id pub-id-type="pmid">34161051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ravi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sonpavde</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jacene</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>1163</fpage>
            <page-range>1163-1175</page-range>
            <pub-id pub-id-type="pmid">36305305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buteau</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Emmett</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Iravani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joshua</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Azad</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>McJannett</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Stockler</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>MS</given-names>
              </name>
              <collab>TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group</collab>
            </person-group>
            <article-title>PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1389</fpage>
            <page-range>1389-1397</page-range>
            <pub-id pub-id-type="pmid">36261050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rohith</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>VISION trial: <sup>177</sup>Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer.</article-title>
            <source>Indian J Urol</source>
            <year>2021</year>
            <season>Oct-Dec</season>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>372</fpage>
            <page-range>372-373</page-range>
            <pub-id pub-id-type="pmid">34759536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filippi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chiaravalloti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schillaci</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cianni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bagni</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Theranostic approaches in nuclear medicine: current status and future prospects.</article-title>
            <source>Expert Rev Med Devices</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-343</page-range>
            <pub-id pub-id-type="pmid">32157920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miederer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Alpha emitting nuclides in nuclear medicine theranostics.</article-title>
            <source>Nuklearmedizin</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-279</page-range>
            <pub-id pub-id-type="pmid">34624903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferdinandus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fendler</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Morigi</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Theranostics in oncology: What radiologists want to know.</article-title>
            <source>Eur J Radiol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>142</volume>
            <fpage>109875</fpage>
            <pub-id pub-id-type="pmid">34391057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmadzadehfar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matern</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kessel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>B&#x000f6;gemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kratochwil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rathke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ilhan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Svirydenka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sathekge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kabasakal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yordanova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia-Perez</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Kairemo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maharaj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Virgolini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rahbar</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [<sup>177</sup>Lu]Lu-PSMA-617: a WARMTH multicentre study.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>12</issue>
            <fpage>4067</fpage>
            <page-range>4067-4076</page-range>
            <pub-id pub-id-type="pmid">34031719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Kruijff</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wolterbeek</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Denkova</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2015</year>
            <month>Jun</month>
            <day>10</day>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>321</fpage>
            <page-range>321-36</page-range>
            <pub-id pub-id-type="pmid">26066613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lassmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nosske</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reiners</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Therapy of ankylosing spondylitis with 224Ra-radium chloride: dosimetry and risk considerations.</article-title>
            <source>Radiat Environ Biophys</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-8</page-range>
            <pub-id pub-id-type="pmid">12373325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgenstern</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bruchertseifer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Apostolidis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.</article-title>
            <source>Curr Radiopharm</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-7</page-range>
            <pub-id pub-id-type="pmid">22642390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feuerecker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tauber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knorr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beheshti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seidl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruchertseifer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pickhard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gafita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kratochwil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Retz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>D'Alessandria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morgenstern</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eiber</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.</article-title>
            <source>Eur Urol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>343</fpage>
            <page-range>343-350</page-range>
            <pub-id pub-id-type="pmid">33293081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birindelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drobnjakovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morath</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Steiger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>D'Alessandria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gourni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Afshar-Oromieh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rominger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eiber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy.</article-title>
            <source>Annu Int Conf IEEE Eng Med Biol Soc</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>2021</volume>
            <fpage>4497</fpage>
            <page-range>4497-4500</page-range>
            <pub-id pub-id-type="pmid">34892217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneda-Nakashima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shirakami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kadonaga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ooe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Haba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Toyoshima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cardinale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giesel</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Tomiyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fukase</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Targeted &#x003b1;-therapy using astatine (<sup>211</sup>At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>849</fpage>
            <page-range>849-858</page-range>
            <pub-id pub-id-type="pmid">36344651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical advancement of precision theranostics in prostate cancer.</article-title>
            <source>Front Oncol</source>
            <year>2023</year>
            <volume>13</volume>
            <fpage>1072510</fpage>
            <pub-id pub-id-type="pmid">36816956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanli</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuyumcu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simsek</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>B&#x000fc;y&#x000fc;kkaya</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Civan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Isik</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Ozkan</surname>
                <given-names>ZG</given-names>
              </name>
              <name>
                <surname>Basaran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanli</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: A Single-Center Experience.</article-title>
            <source>Clin Nucl Med</source>
            <year>2021</year>
            <month>Dec</month>
            <day>01</day>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>943</fpage>
            <page-range>943-951</page-range>
            <pub-id pub-id-type="pmid">34593693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sindhu</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Nehlsen</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Radium-223 for Metastatic Castrate-Resistant Prostate Cancer.</article-title>
            <source>Pract Radiat Oncol</source>
            <year>2022</year>
            <season>Jul-Aug</season>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>312</fpage>
            <page-range>312-316</page-range>
            <pub-id pub-id-type="pmid">35717046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaise</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horiguchi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Takao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Narui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tawaraya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Machida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akazawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>T</given-names>
              </name>
              <collab>JONIE Study Group</collab>
            </person-group>
            <article-title>Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.</article-title>
            <source>J Bone Miner Metab</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>998</fpage>
            <page-range>998-1006</page-range>
            <pub-id pub-id-type="pmid">36042056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Correa-Gonz&#x000e1;lez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Arteaga de Murphy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pichardo-Romero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedraza-L&#x000f3;pez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moreno-Garc&#x000ed;a</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Correa-Hern&#x000e1;ndez</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>(153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.</article-title>
            <source>Arch Med Res</source>
            <year>2014</year>
            <month>May</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-8</page-range>
            <pub-id pub-id-type="pmid">24681187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van de Voorde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duchemin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heinke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chevallay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Van Stenis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cocolios</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Cardinaels</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ponsard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ooms</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stora</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burgoyne</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>675221</fpage>
            <pub-id pub-id-type="pmid">34350194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caracciolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Urso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Borgia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ortolan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Uccelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cittanti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castellani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartolomei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lazzeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopci</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Role of [<sup>68</sup>Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Oct</month>
            <day>14</day>
            <volume>14</volume>
            <issue>20</issue>
            <pub-id pub-id-type="pmid">36291820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pepe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pepe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tamburo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marletta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pennisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fraggetta</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.</article-title>
            <source>Arch Ital Urol Androl</source>
            <year>2022</year>
            <month>Sep</month>
            <day>26</day>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-277</page-range>
            <pub-id pub-id-type="pmid">36165469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rajwa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sari Motlagh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mostafaei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Quhal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Laukhtina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aydh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pallauf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pradere</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ceci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baltzer</surname>
                <given-names>PAT</given-names>
              </name>
              <name>
                <surname>Hacker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rasul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karakiewicz</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nasu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.</article-title>
            <source>Eur Urol Oncol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>390</fpage>
            <page-range>390-400</page-range>
            <pub-id pub-id-type="pmid">35715320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Bayati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grueneisen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000fc;tje</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sawicki</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Suntharalingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tschirdewahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Forsting</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000fc;bben</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Umutlu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wetter</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.</article-title>
            <source>Urol Int</source>
            <year>2018</year>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-171</page-range>
            <pub-id pub-id-type="pmid">29393268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grubm&#x000fc;ller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Baltzer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hartenbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Helbich</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Haug</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Goldner</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Wadsak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pfaff</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mitterhauser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berroteran-Infante</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grahovac</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Babich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Susani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kenner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Hacker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hartenbach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.</article-title>
            <source>Clin Cancer Res</source>
            <year>2018</year>
            <month>Dec</month>
            <day>15</day>
            <volume>24</volume>
            <issue>24</issue>
            <fpage>6300</fpage>
            <page-range>6300-6307</page-range>
            <pub-id pub-id-type="pmid">30139879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muehlematter</surname>
                <given-names>UJ</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Schawkat</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>H&#x000f6;tker</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rupp</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>R&#x000fc;schoff</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Eberli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>OF</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Accuracy of Multiparametric MRI versus <sup>68</sup>Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.</article-title>
            <source>Radiology</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>293</volume>
            <issue>2</issue>
            <fpage>350</fpage>
            <page-range>350-358</page-range>
            <pub-id pub-id-type="pmid">31502937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abiodun-Ojo</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Jani</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Akintayo</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Akin-Akintayo</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Odewole</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Tade</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Master</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Fielder</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Halkar</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on <sup>18</sup>F-Fluciclovine PET/CT Guidance.</article-title>
            <source>J Nucl Med</source>
            <year>2021</year>
            <month>Aug</month>
            <day>01</day>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>1089</fpage>
            <page-range>1089-1096</page-range>
            <pub-id pub-id-type="pmid">33517323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eiber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwaiger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Combs</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Habl</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.</article-title>
            <source>Radiat Oncol</source>
            <year>2016</year>
            <month>May</month>
            <day>26</day>
            <volume>11</volume>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">27229485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jani</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Schreibmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Halkar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hershatter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Shelton</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Master</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kucuk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Carthon</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Bilen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Abiodun-Ojo</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Akintayo</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dhere</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title><sup>18</sup>F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>May</month>
            <day>22</day>
            <volume>397</volume>
            <issue>10288</issue>
            <fpage>1895</fpage>
            <page-range>1895-1904</page-range>
            <pub-id pub-id-type="pmid">33971152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lawrentschuk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vela</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frydenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shakher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Taubman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ting Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nottage</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marusic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herschtal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iravani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>DG</given-names>
              </name>
              <collab>proPSMA Study Group Collaborators</collab>
            </person-group>
            <article-title>Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Apr</month>
            <day>11</day>
            <volume>395</volume>
            <issue>10231</issue>
            <fpage>1208</fpage>
            <page-range>1208-1216</page-range>
            <pub-id pub-id-type="pmid">32209449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145334.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eulau</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hauke</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kendi</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>115</volume>
            <fpage>102524</fpage>
            <pub-id pub-id-type="pmid">36933329</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
